Testing a new antibiotic for mycobacterium abscessus lung infection
Treatments studied
Part of Infections clinical trials.
This study tests if a drug called sitafloxacin can quickly kill mycobacterium abscessus bacteria in the lungs. It may help people with this hard-to-treat infection find a more effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a lung infection caused by mycobacterium abscessus in the past 6 months.
- You agree to use birth control during the study.
- You have not taken steroids or immune-suppressing drugs in the last 90 days.
- You are not pregnant or breastfeeding.
- Your infection is not resistant to fluoroquinolone antibiotics, and you are not allergic to them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This study tests if adding traditional Chinese medicine to standard treatment helps people with a lung infection called Mycobacterium abscessus. It may improve recovery and reduce side effects.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
This trial tests a new combination of antibiotics to treat a hard-to-cure lung infection caused by Mycobacterium abscessus. It compares the new combination to the standard treatment, and people with cystic fibrosis and those without can take part.
This study tests whether an antibiotic called rifabutin works better for treating a difficult lung infection (Mycobacterium abscessus) that resists a common antibiotic. You may qualify if you've been diagnosed with this infection and your lab tests show it can resist clarithromycin.
Hear when a new Fluoroquinolone trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.